Evotec SE (EVO) Cash from Investing Activities (2009 - 2026)

Evotec SE (EVO) reported Cash from Investing Activities of -$14557.1 for Q1 2026, up 35.95% on a YoY basis from -$10707.6 in Q1 2025, and down 100.01% sequentially from $199.8 million in Q4 2025.

Evotec SE (EVO) Cash from Investing Activities (2009 - 2026) Analysis & Trends

Evotec SE (EVO) has 9 years of Cash from Investing Activities data on file, last reported at -$14557.1 in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Investing Activities rose 35.95% year-over-year to -$14557.1; the trailing twelve-month figure through Mar 2026 stood at $199.8 million (up 362.62% YoY), and the FY2025 full-year result was $199.7 million, up 362.57% from the prior year.
  • Cash from Investing Activities retreated to -$14557.1 in Q1 2026, from $199.8 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $199.8 million in Q4 2025 to a low of -$420.7 million in Q4 2022.
  • A 5-year average of -$18.3 million and a median of -$28464.8 in 2024 frame the typical range for Cash from Investing Activities.
  • Across the five-year window, Cash from Investing Activities plunged 191439.37% in 2022 and surged 362.98% in 2025, its largest moves.
  • Tracing EVO's Cash from Investing Activities over 5 years: stood at -$420.7 million in 2022, then jumped by 96.6% to -$14.3 million in 2023, then sank by 430.62% to -$76.0 million in 2024, then surged by 362.98% to $199.8 million in 2025, then sank by 100.01% to -$14557.1 in 2026.
  • Business Quant data shows EVO's Cash from Investing Activities at -$14557.1 in Q1 2026, $199.8 million in Q4 2025, and -$8465.1 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 89.55 Bn 87.69 Bn - -
2 Teva Pharmaceutical Industries 36.00 Bn 32.26 Bn 1.97 Bn 229.00 Mn
3 Zoetis 32.59 Bn 30.65 Bn 1.62 Bn -87.00 Mn
4 Takeda Pharmaceutical 27.52 Bn 23.45 Bn 4.39 Bn -369.95 Mn
5 United Therapeutics 23.07 Bn 20.91 Bn 648.10 Mn 743.70 Mn
6 RedHill Biopharma 21.48 Bn 21.48 Bn - -
7 Viatris 20.28 Bn 18.47 Bn 1.16 Bn 277.40 Mn
8 Neurocrine Biosciences 17.78 Bn 16.47 Bn 800.70 Mn -506.20 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -60.00 Mn
10 Evotec SE 345.39 Mn 344.87 Mn - -14,557.05

Historic Data

Download Data
DateValue
Mar 31, 2026 -14,557.05
Mar 31, 2026 -14,557.05
Dec 31, 2025 199.80 Mn
Dec 31, 2025 199.80 Mn
Sep 30, 2025 -8,465.13
Sep 30, 2025 -8,465.13
Jun 30, 2025 -24,838.59
Jun 30, 2025 -24,838.59
Mar 31, 2025 -22,728.07
Mar 31, 2025 -22,728.07
Dec 31, 2024 -75.98 Mn
Dec 31, 2024 -75.98 Mn
Sep 30, 2024 -28,464.75
Sep 30, 2024 -28,464.75
Jun 30, 2024 -33,687.20
Jun 30, 2024 -33,687.20
Mar 31, 2024 -33,576.18
Mar 31, 2024 -33,576.18
Dec 31, 2023 -14.32 Mn
Dec 31, 2023 -14.32 Mn